A new study, authored by KBH Professor Jan Inge Henter and published in the New England Journal of Medicine, has investigated whether the drug empagliflozin can reduce the risk of heart failure and death in patients who have ...
Feb 20, 2025
0
31
A team of scientists at the Centro Nacional de Investigaciones Cardiovasculares (CNIC), working in collaboration with international partners, has designed a strategy for preventing the cardiotoxic effects of anthracyclines, ...
Feb 4, 2025
0
22
An investigation led by Brigham and Women's Hospital finds empagliflozin (sold as Jardiance) may reduce the risk of diabetic retinopathy (DR) progression in patients with a history of nonproliferative diabetic retinopathy ...
Empagliflozin continues to offer cardiorenal benefits for up to 12 months after discontinuation among patients with chronic kidney disease at risk for progression, according to a study published online Oct. 25 in the New ...
Oct 28, 2024
0
17
The SGLT2 inhibitor empagliflozin confers kidney-protective benefits and can therefore be given safely and effectively to patients when they are hospitalized for acute myocardial infarction (MI), a Mount Sinai-led global ...
Sep 2, 2024
0
29
Spurred by fed-up consumers, states are trying to curb spiraling prescription drug costs by assembling special public boards to investigate and regulate pricing.
Jul 22, 2024
0
30
Intermittent fasting may be a more effective intervention than drugs for people with early diabetes and either obesity or overweight, according to a study published online June 21 in JAMA Network Open.
Jun 25, 2024
0
67
Initially, diabetes drugs like Ozempic and Wegovy showed promise in weight loss and have subsequently been marketed and widely used for weight loss. Now these medications are showing promise as a possible treatment for multiple ...
Apr 15, 2024
0
173
For patients with acute myocardial infarction at risk for heart failure, empagliflozin reduces the risk for heart failure hospitalization, according to a study published online April 6 in Circulation to coincide with the ...
Apr 8, 2024
0
60
While the composite of death and heart failure hospitalizations was not significantly reduced, empagliflozin may help reduce heart failure risks after a heart attack
Apr 8, 2024
0
62
